Alan Lotvin
Insider
First SEC filing: July 13, 2022 · Latest: July 13, 2022
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | PROK | A | 135,000 | · | · | 135,000 Direct | · | Acquired | (price as of 2026-10-05) |
| May 29, 2025 | PROK | A | 125,862 | · | · | 125,862 Direct | · | Acquired | (price as of 2026-10-05) |
| May 30, 2024 | PROK | A | 62,558 | · | · | 62,558 Direct | · | Acquired | (price as of 2026-10-05) |
| June 29, 2023 | PROK | A | 48,128 | · | · | 48,128 Direct | · | Acquired | (price as of 2026-10-05) |
| Aug. 4, 2022 | CVS | M | 22,541 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-05) |
| Aug. 4, 2022 | CVS | S 10b5-1 | 22,541 | $104.00 | $2,344,264 | 109,183 Direct | -17.11% | Disposed | -16.3% (price as of 2026-10-05) |
| Aug. 4, 2022 | CVS | M | 22,541 | $62.21 | $1,402,276 | 131,724 Direct | +20.65% | Acquired | 39.9% (price as of 2026-10-05) |
| Aug. 3, 2022 | CVS | M | 50,501 | · | · | 20,201 Direct | -71.43% | Disposed | (price as of 2026-10-05) |
| Aug. 3, 2022 | CVS | M | 70,398 | · | · | 70,399 Direct | -50.00% | Disposed | (price as of 2026-10-05) |
| Aug. 3, 2022 | CVS | S 10b5-1 | 50,501 | $98.00 | $4,949,098 | 109,183 Direct | -31.63% | Disposed | -11.2% (price as of 2026-10-05) |
| Aug. 3, 2022 | CVS | M | 50,501 | $54.19 | $2,736,649 | 159,684 Direct | +46.25% | Acquired | 60.6% (price as of 2026-10-05) |
| Aug. 3, 2022 | CVS | S 10b5-1 | 70,398 | $98.00 | $6,899,004 | 109,183 Direct | -39.20% | Disposed | -11.2% (price as of 2026-10-05) |
| Aug. 3, 2022 | CVS | M | 70,398 | $58.34 | $4,107,019 | 179,581 Direct | +64.48% | Acquired | 49.1% (price as of 2026-10-05) |
| July 11, 2022 | PROK | A | 1,514,326 | · | · | 1,514,326 Direct | · | Acquired | (price as of 2026-10-05) |
| July 11, 2022 | PROK | A | 1,514,326 | · | · | 1,514,326 Direct | · | Acquired | (price as of 2026-10-05) |
| April 1, 2022 | CVS | A | 77,962 | $101.09 | $7,881,179 | 77,962 Direct | · | Acquired | -13.9% (price as of 2026-10-05) |
| April 1, 2022 | CVS | F | 38,129 | $101.09 | $3,854,461 | 109,183 Direct | -25.88% | Disposed | -13.9% (price as of 2026-10-05) |
| Feb. 21, 2022 | CVS | A | 85,971 | · | · | 147,312 Direct | +140.15% | Acquired | (price as of 2026-10-05) |
| Feb. 1, 2022 | CVS | M | 21,386 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-05) |
| Feb. 1, 2022 | CVS | S 10b5-1 | 21,386 | $106.50 | $2,277,609 | 61,341 Direct | -25.85% | Disposed | -18.3% (price as of 2026-10-05) |
| Feb. 1, 2022 | CVS | M | 21,386 | $102.26 | $2,186,932 | 82,727 Direct | +34.86% | Acquired | -14.9% (price as of 2026-10-05) |
| Dec. 27, 2021 | CVS | F | 200 | $88.78 | $17,756 | 5,827 Direct | -3.32% | Disposed | -2.0% (price as of 2026-10-05) |
| June 28, 2021 | CVS | S 10b5-1 | 2,781 | $83.67 | $232,686 | 61,048 Direct | -4.36% | Disposed | 4.0% (price as of 2026-10-05) |
| April 3, 2021 | CVS | F | 1,705 | $74.30 | $126,682 | 63,829 Direct | -2.60% | Disposed | 17.1% (price as of 2026-10-05) |
| April 1, 2021 | CVS | F | 42,431 | · | · | 61,691 Direct | -40.75% | Disposed | (price as of 2026-10-05) |
| April 1, 2021 | CVS | A | 120,940 | $74.30 | $8,985,842 | 120,940 Direct | · | Acquired | 17.1% (price as of 2026-10-05) |
| Feb. 1, 2021 | CVS | A | 95,669 | · | · | 104,122 Direct | +1131.78% | Acquired | (price as of 2026-10-05) |
| Jan. 8, 2021 | CVS | M | 15,736 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-05) |
| Jan. 8, 2021 | CVS | M | 10,100 | · | · | 70,702 Direct | -12.50% | Disposed | (price as of 2026-10-05) |
| Jan. 8, 2021 | CVS | S 10b5-1 | 25,836 | $75.00 | $1,937,700 | 8,369 Direct | -75.53% | Disposed | 16.0% (price as of 2026-10-05) |
| Jan. 8, 2021 | CVS | M | 15,736 | $74.29 | $1,169,027 | 34,205 Direct | +85.20% | Acquired | 17.1% (price as of 2026-10-05) |
| Jan. 8, 2021 | CVS | M | 10,100 | $54.19 | $547,319 | 18,469 Direct | +120.68% | Acquired | 60.6% (price as of 2026-10-05) |
| Nov. 13, 2020 | CVS | S 10b5-1 | 7,138 | $70.00 | $499,660 | 8,023 Direct | -47.08% | Disposed | 24.3% (price as of 2026-10-05) |
| May 11, 2020 | CVS | P | 5,000 | $63.14 | $315,700 | 15,161 Direct | +49.21% | Acquired | 37.8% (price as of 2026-10-05) |
| April 1, 2020 | CVS | A | 140,797 | · | · | 140,797 Direct | · | Acquired | (price as of 2026-10-05) |
| April 1, 2020 | CVS | A | 140,797 | $58.61 | $8,252,112 | 140,797 Direct | · | Acquired | 48.5% (price as of 2026-10-05) |
| April 1, 2020 | CVS | F | 1,481 | $58.34 | $86,402 | 10,161 Direct | -12.72% | Disposed | 49.1% (price as of 2026-10-05) |
| Feb. 28, 2020 | CVS | A | 11,828 | $59.18 | $699,981 | 27,945 Direct | +73.39% | Acquired | 47.0% (price as of 2026-10-05) |
| Feb. 28, 2020 | CVS | F | 160 | $59.18 | $9,469 | 8,303 Direct | -1.89% | Disposed | 47.0% (price as of 2026-10-05) |
| April 1, 2019 | CVS | A | 80,802 | $54.19 | $4,378,660 | 80,802 Direct | · | Acquired | 60.6% (price as of 2026-10-05) |
| April 1, 2019 | CVS | F | 863 | $54.19 | $46,766 | 7,578 Direct | -10.22% | Disposed | 60.6% (price as of 2026-10-05) |
| Feb. 28, 2019 | CVS | A | 6,342 | $57.83 | $366,758 | 15,141 Direct | +72.08% | Acquired | 50.5% (price as of 2026-10-05) |
| Feb. 28, 2019 | CVS | F | 292 | $57.83 | $16,886 | 5,508 Direct | -5.03% | Disposed | 50.5% (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | PROK | Director stock option (right to buy) | Class A Common Stock | $1.81 | May 28, 2036 | 135,000 | Acquired |
| May 29, 2025 | PROK | Director stock option (right to buy) | Class A Ordinary Shares | $0.72 | May 29, 2035 | 125,862 | Acquired |
| May 30, 2024 | PROK | Director stock option (right to buy) | Class A Ordinary Shares | $4.20 | May 30, 2034 | 62,558 | Acquired |
| June 29, 2023 | PROK | Director stock option (right to buy) | Class A Ordinary Shares | $10.56 | June 29, 2033 | 48,128 | Acquired |
| Aug. 4, 2022 | CVS | Stock Option | Common Stock | $62.21 | April 1, 2025 | 22,541 | Disposed |
| Aug. 3, 2022 | CVS | Stock Option | Common Stock | $54.19 | April 1, 2029 | 50,501 | Disposed |
| Aug. 3, 2022 | CVS | Stock Option | Common Stock | · | April 1, 2030 | 70,398 | Disposed |
| July 11, 2022 | PROK | Common Units in ProKidney LP [F3] | Class A Ordinary Shares | · | · | 1,514,326 | Acquired |
| July 11, 2022 | PROK | Class B Ordinary Shares | Class A Ordinary Shares | · | · | 1,514,326 | Acquired |
| April 1, 2022 | CVS | Stock Option | Common Stock | $101.09 | April 1, 2032 | 77,962 | Acquired |
| Feb. 1, 2022 | CVS | Stock Option | Common Stock | $102.26 | April 1, 2022 | 21,386 | Disposed |
| April 1, 2021 | CVS | Stock Option | Common Stock | $74.30 | April 1, 2031 | 120,940 | Acquired |
| Jan. 8, 2021 | CVS | Stock Option | Common Stock | $74.29 | April 1, 2021 | 15,736 | Disposed |
| Jan. 8, 2021 | CVS | Stock Option | Common Stock | $54.19 | April 1, 2029 | 10,100 | Disposed |
| April 1, 2020 | CVS | Stock Option | Common Stock | · | April 1, 2030 | 140,797 | Acquired |
| April 1, 2020 | CVS | Stock Option | Common Stock | · | April 1, 2030 | 140,797 | Acquired |
| April 1, 2019 | CVS | Stock Option | Common Stock | $54.19 | April 1, 2029 | 80,802 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 16 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| July 13, 2022 | PROK | No securities owned. | 0 | Direct |
| June 8, 2018 | CVS | Common Stock | 4,512 | Direct |
| June 8, 2018 | CVS | Common Stock | · | Indirect |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Common Stock (restricted) | · | Direct |
| June 8, 2018 | CVS | Stock Unit | · | Direct |
| June 8, 2018 | CVS | Stock Option | 15,736 | Direct |
| June 8, 2018 | CVS | Stock Option | 21,386 | Direct |
| June 8, 2018 | CVS | Stock Option | 27,395 | Direct |
| June 8, 2018 | CVS | Stock Option | 32,911 | Direct |
| June 8, 2018 | CVS | Stock Option | 22,541 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $1,000,000 | · | $5,624,957 | $1,874,986 | $2,242,000 | · | $241,807 | $10,983,750 |
| 2020 | $831,250 | · | · | · | $1,577,000 | · | $83,035 | $7,472,175 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.